ID   RYR2_RAT                Reviewed;        4953 AA.
AC   B0LPN4; D7UNT3;
DT   22-FEB-2012, integrated into UniProtKB/Swiss-Prot.
DT   22-FEB-2012, sequence version 2.
DT   24-JUL-2024, entry version 123.
DE   RecName: Full=Ryanodine receptor 2 {ECO:0000305|PubMed:20471962};
DE            Short=RYR-2;
DE            Short=RyR2;
DE   AltName: Full=Cardiac muscle ryanodine receptor;
DE   AltName: Full=Cardiac muscle ryanodine receptor-calcium release channel;
DE   AltName: Full=Type 2 ryanodine receptor;
GN   Name=Ryr2 {ECO:0000312|RGD:620314};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   STRAIN=Sprague-Dawley; TISSUE=Cerebral artery;
RX   PubMed=20445169; DOI=10.1152/ajpcell.00318.2009;
RA   Vaithianathan T., Narayanan D., Asuncion-Chin M.T., Jeyakumar L.H., Liu J.,
RA   Fleischer S., Jaggar J.H., Dopico A.M.;
RT   "Subtype identification and functional characterization of ryanodine
RT   receptors in rat cerebral artery myocytes.";
RL   Am. J. Physiol. 299:C264-C278(2010).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Pancreatic islet;
RX   PubMed=20471962; DOI=10.1016/j.bbrc.2010.05.051;
RA   Takasawa S., Kuroki M., Nata K., Noguchi N., Ikeda T., Yamauchi A., Ota H.,
RA   Itaya-Hironaka A., Sakuramoto-Tsuchida S., Takahashi I., Yoshikawa T.,
RA   Shimosegawa T., Okamoto H.;
RT   "A novel ryanodine receptor expressed in pancreatic islets by alternative
RT   splicing from type 2 ryanodine receptor gene.";
RL   Biochem. Biophys. Res. Commun. 397:140-145(2010).
RN   [3]
RP   PHOSPHORYLATION AT SER-2798 AND SER-2804, AND TISSUE SPECIFICITY.
RX   PubMed=18755143; DOI=10.1016/j.bbrc.2008.08.084;
RA   Huke S., Bers D.M.;
RT   "Ryanodine receptor phosphorylation at serine 2030, 2808 and 2814 in rat
RT   cardiomyocytes.";
RL   Biochem. Biophys. Res. Commun. 376:80-85(2008).
RN   [4]
RP   FUNCTION, INTERACTION WITH FKBP1A AND FKBP1B, AND TISSUE SPECIFICITY.
RX   PubMed=20431056; DOI=10.1161/circresaha.110.219816;
RA   Guo T., Cornea R.L., Huke S., Camors E., Yang Y., Picht E., Fruen B.R.,
RA   Bers D.M.;
RT   "Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized
RT   cardiac myocytes and effects on Ca sparks.";
RL   Circ. Res. 106:1743-1752(2010).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1334; SER-1863; SER-2021;
RP   SER-2687; SER-2798; SER-2801 AND SER-2804, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [6]
RP   STRUCTURE BY NMR OF 3561-3572 IN COMPLEX WITH S100A1, AND INTERACTION WITH
RP   CALM AND S100A1.
RX   PubMed=18650434; DOI=10.1074/jbc.m804432200;
RA   Wright N.T., Prosser B.L., Varney K.M., Zimmer D.B., Schneider M.F.,
RA   Weber D.J.;
RT   "S100A1 and calmodulin compete for the same binding site on ryanodine
RT   receptor.";
RL   J. Biol. Chem. 283:26676-26683(2008).
CC   -!- FUNCTION: Cytosolic calcium-activated calcium channel that mediates the
CC       release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and
CC       thereby plays a key role in triggering cardiac muscle contraction.
CC       Aberrant channel activation can lead to cardiac arrhythmia. In cardiac
CC       myocytes, calcium release is triggered by increased Ca(2+) cytosolic
CC       levels due to activation of the L-type calcium channel CACNA1C. The
CC       calcium channel activity is modulated by formation of heterotetramers
CC       with RYR3. Required for cellular calcium ion homeostasis. Required for
CC       embryonic heart development. {ECO:0000250|UniProtKB:Q92736,
CC       ECO:0000269|PubMed:20431056, ECO:0000269|PubMed:20471962}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671,
CC         ChEBI:CHEBI:29108; Evidence={ECO:0000250|UniProtKB:Q92736};
CC   -!- ACTIVITY REGULATION: The calcium release is activated by increased
CC       cytosolic calcium levels, by nitric oxyde (NO), caffeine and ATP.
CC       Channel activity is modulated by the alkaloid ryanodine that binds to
CC       the open Ca-release channel with high affinity. At low concentrations,
CC       ryanodine maintains the channel in an open conformation. High ryanodine
CC       concentrations inhibit channel activity. Channel activity is regulated
CC       by calmodulin (CALM). Channel activity is inhibited by magnesium ions,
CC       possibly by competition for calcium binding sites.
CC       {ECO:0000250|UniProtKB:P11716}.
CC   -!- SUBUNIT: Homotetramer. Can also form heterotetramers with RYR3.
CC       Identified in a complex composed of RYR2, FKBP1B, PKA catalytic
CC       subunit, PRKAR2A, AKAP6, and the protein phosphatases PP2A and PP1.
CC       Interacts directly with FKBP1B, PKA, PP1 and PP2A (By similarity).
CC       Interacts with FKBP1A and FKBP1B; these interactions may stabilize the
CC       channel in its closed state and prevent Ca(2+) leaks. Interacts with
CC       CALM and S100A1; these interactions regulate channel activity.
CC       Interacts with SELENON (By similarity). In cardiac muscles, identified
CC       in a complex composed of FSD2, CMYA5 and RYR2 (By similarity).
CC       {ECO:0000250|UniProtKB:E9Q401, ECO:0000250|UniProtKB:P30957,
CC       ECO:0000250|UniProtKB:Q92736, ECO:0000269|PubMed:18650434,
CC       ECO:0000269|PubMed:20431056}.
CC   -!- SUBCELLULAR LOCATION: Sarcoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:Q92736}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=B0LPN4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=B0LPN4-2; Sequence=VSP_042299, VSP_042300;
CC   -!- TISSUE SPECIFICITY: Detected in heart muscle myocytes (at protein
CC       level). Widely expressed. Detected in heart muscle and cerebral artery
CC       smooth muscle. Detected in pancreatic islet cells.
CC       {ECO:0000269|PubMed:18755143, ECO:0000269|PubMed:20431056,
CC       ECO:0000269|PubMed:20445169, ECO:0000269|PubMed:20471962}.
CC   -!- DOMAIN: The calcium release channel activity resides in the C-terminal
CC       region while the remaining part of the protein resides in the
CC       cytoplasm. {ECO:0000250|UniProtKB:P11716}.
CC   -!- PTM: Channel activity is modulated by phosphorylation. Phosphorylation
CC       at Ser-2798 and Ser-2804 increases the open probability of the calcium
CC       channel. Phosphorylation is increased in failing heart, leading to
CC       calcium leaks and increased cytoplasmic Ca(2+) levels (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Ser-2021 by PKA enhances the response to
CC       lumenal calcium. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the ryanodine receptor (TC 1.A.3.1) family. RYR2
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; EU346200; ABY79796.1; -; mRNA.
DR   EMBL; AB204523; BAJ10276.1; -; mRNA.
DR   RefSeq; NP_001177972.1; NM_001191043.1. [B0LPN4-2]
DR   RefSeq; NP_114467.1; NM_032078.2.
DR   PDB; 2K2F; NMR; -; C/D=3561-3572.
DR   PDBsum; 2K2F; -.
DR   SMR; B0LPN4; -.
DR   BioGRID; 604379; 4.
DR   CORUM; B0LPN4; -.
DR   IntAct; B0LPN4; 1.
DR   STRING; 10116.ENSRNOP00000059019; -.
DR   BindingDB; B0LPN4; -.
DR   ChEMBL; CHEMBL3388; -.
DR   DrugCentral; B0LPN4; -.
DR   CarbonylDB; B0LPN4; -.
DR   GlyGen; B0LPN4; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; B0LPN4; -.
DR   PhosphoSitePlus; B0LPN4; -.
DR   SwissPalm; B0LPN4; -.
DR   PaxDb; 10116-ENSRNOP00000059019; -.
DR   PeptideAtlas; B0LPN4; -.
DR   ABCD; B0LPN4; 1 sequenced antibody.
DR   GeneID; 689560; -.
DR   KEGG; rno:689560; -.
DR   AGR; RGD:620314; -.
DR   CTD; 6262; -.
DR   RGD; 620314; Ryr2.
DR   eggNOG; KOG2243; Eukaryota.
DR   InParanoid; B0LPN4; -.
DR   OrthoDB; 3144451at2759; -.
DR   Reactome; R-RNO-2672351; Stimuli-sensing channels.
DR   Reactome; R-RNO-5578775; Ion homeostasis.
DR   EvolutionaryTrace; B0LPN4; -.
DR   PRO; PR:B0LPN4; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0031672; C:A band; IDA:RGD.
DR   GO; GO:0034704; C:calcium channel complex; ISO:RGD.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:RGD.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0005635; C:nuclear envelope; IDA:BHF-UCL.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0042383; C:sarcolemma; IDA:RGD.
DR   GO; GO:0030017; C:sarcomere; ISO:RGD.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IDA:BHF-UCL.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0030018; C:Z disc; IDA:BHF-UCL.
DR   GO; GO:0005262; F:calcium channel activity; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0048763; F:calcium-induced calcium release activity; IDA:RGD.
DR   GO; GO:0005516; F:calmodulin binding; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0015278; F:intracellularly gated calcium channel activity; ISS:UniProtKB.
DR   GO; GO:0097159; F:organic cyclic compound binding; ISO:RGD.
DR   GO; GO:0034236; F:protein kinase A catalytic subunit binding; ISO:RGD.
DR   GO; GO:0034237; F:protein kinase A regulatory subunit binding; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:0005219; F:ryanodine-sensitive calcium-release channel activity; IDA:RGD.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0043924; F:suramin binding; ISO:RGD.
DR   GO; GO:0097553; P:calcium ion transmembrane import into cytosol; ISO:RGD.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IMP:RGD.
DR   GO; GO:0006816; P:calcium ion transport; ISS:UniProtKB.
DR   GO; GO:0060402; P:calcium ion transport into cytosol; ISO:RGD.
DR   GO; GO:0019722; P:calcium-mediated signaling; ISS:UniProtKB.
DR   GO; GO:0060048; P:cardiac muscle contraction; ISO:RGD.
DR   GO; GO:0003300; P:cardiac muscle hypertrophy; ISO:RGD.
DR   GO; GO:0071313; P:cellular response to caffeine; ISS:UniProtKB.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; ISO:RGD.
DR   GO; GO:0005513; P:detection of calcium ion; ISO:RGD.
DR   GO; GO:0003143; P:embryonic heart tube morphogenesis; ISS:UniProtKB.
DR   GO; GO:0051649; P:establishment of localization in cell; ISO:RGD.
DR   GO; GO:0072599; P:establishment of protein localization to endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0006874; P:intracellular calcium ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0003220; P:left ventricular cardiac muscle tissue morphogenesis; ISO:RGD.
DR   GO; GO:0071421; P:manganese ion transmembrane transport; IMP:RGD.
DR   GO; GO:0034220; P:monoatomic ion transmembrane transport; IMP:RGD.
DR   GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; IDA:RGD.
DR   GO; GO:0010460; P:positive regulation of heart rate; ISO:RGD.
DR   GO; GO:0051284; P:positive regulation of sequestering of calcium ion; ISO:RGD.
DR   GO; GO:0098735; P:positive regulation of the force of heart contraction; ISO:RGD.
DR   GO; GO:0086029; P:Purkinje myocyte to ventricular cardiac muscle cell signaling; ISO:RGD.
DR   GO; GO:0098910; P:regulation of atrial cardiac muscle cell action potential; ISO:RGD.
DR   GO; GO:0098904; P:regulation of AV node cell action potential; ISO:RGD.
DR   GO; GO:0055117; P:regulation of cardiac muscle contraction; ISO:RGD.
DR   GO; GO:0010882; P:regulation of cardiac muscle contraction by calcium ion signaling; ISO:RGD.
DR   GO; GO:0010881; P:regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion; ISO:RGD.
DR   GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; IMP:RGD.
DR   GO; GO:0002027; P:regulation of heart rate; ISO:RGD.
DR   GO; GO:0098907; P:regulation of SA node cell action potential; ISO:RGD.
DR   GO; GO:0098911; P:regulation of ventricular cardiac muscle cell action potential; ISO:RGD.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; ISO:RGD.
DR   GO; GO:0014808; P:release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0031000; P:response to caffeine; ISO:RGD.
DR   GO; GO:0051592; P:response to calcium ion; IDA:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IEP:RGD.
DR   GO; GO:0032026; P:response to magnesium ion; IDA:RGD.
DR   GO; GO:0014850; P:response to muscle activity; ISO:RGD.
DR   GO; GO:0035994; P:response to muscle stretch; ISO:RGD.
DR   GO; GO:0007584; P:response to nutrient; IEP:RGD.
DR   GO; GO:0051775; P:response to redox state; ISO:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0070296; P:sarcoplasmic reticulum calcium ion transport; IMP:RGD.
DR   GO; GO:0006941; P:striated muscle contraction; IBA:GO_Central.
DR   GO; GO:0097050; P:type B pancreatic cell apoptotic process; ISO:RGD.
DR   GO; GO:0086005; P:ventricular cardiac muscle cell action potential; ISO:RGD.
DR   CDD; cd12877; SPRY1_RyR; 1.
DR   CDD; cd12878; SPRY2_RyR; 1.
DR   CDD; cd12879; SPRY3_RyR; 1.
DR   Gene3D; 1.10.287.70; -; 1.
DR   Gene3D; 1.10.490.160; -; 3.
DR   Gene3D; 2.60.120.920; -; 3.
DR   Gene3D; 2.80.10.50; -; 2.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   Gene3D; 1.25.10.30; IP3 receptor type 1 binding core, RIH domain; 1.
DR   InterPro; IPR001870; B30.2/SPRY.
DR   InterPro; IPR043136; B30.2/SPRY_sf.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR014821; Ins145_P3_rcpt.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR036300; MIR_dom_sf.
DR   InterPro; IPR016093; MIR_motif.
DR   InterPro; IPR013662; RIH_assoc-dom.
DR   InterPro; IPR000699; RIH_dom.
DR   InterPro; IPR013333; Ryan_recept.
DR   InterPro; IPR015925; Ryanodine_IP3_receptor.
DR   InterPro; IPR003032; Ryanodine_rcpt.
DR   InterPro; IPR009460; Ryanrecept_TM4-6.
DR   InterPro; IPR048581; RYDR_Jsol.
DR   InterPro; IPR035910; RyR/IP3R_RIH_dom_sf.
DR   InterPro; IPR035761; SPRY1_RyR.
DR   InterPro; IPR035764; SPRY2_RyR.
DR   InterPro; IPR035762; SPRY3_RyR.
DR   InterPro; IPR003877; SPRY_dom.
DR   PANTHER; PTHR46399; B30.2/SPRY DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR46399:SF7; RYANODINE RECEPTOR 2; 1.
DR   Pfam; PF13499; EF-hand_7; 1.
DR   Pfam; PF08709; Ins145_P3_rec; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   Pfam; PF02815; MIR; 1.
DR   Pfam; PF08454; RIH_assoc; 1.
DR   Pfam; PF06459; RR_TM4-6; 1.
DR   Pfam; PF01365; RYDR_ITPR; 2.
DR   Pfam; PF21119; RYDR_Jsol; 1.
DR   Pfam; PF02026; RyR; 4.
DR   Pfam; PF00622; SPRY; 3.
DR   PRINTS; PR00795; RYANODINER.
DR   SMART; SM00472; MIR; 4.
DR   SMART; SM00449; SPRY; 3.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 2.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF100909; IP3 receptor type 1 binding core, domain 2; 2.
DR   SUPFAM; SSF82109; MIR domain; 2.
DR   PROSITE; PS50188; B302_SPRY; 3.
DR   PROSITE; PS50919; MIR; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Calcium channel;
KW   Calcium transport; Calmodulin-binding; Developmental protein; Ion channel;
KW   Ion transport; Ligand-gated ion channel; Membrane; Phosphoprotein;
KW   Receptor; Reference proteome; Repeat; Sarcoplasmic reticulum;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..4953
FT                   /note="Ryanodine receptor 2"
FT                   /id="PRO_0000415583"
FT   TOPO_DOM        1..4218
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4219..4239
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4265..4285
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4489..4509
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4566..4586
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4716..4736
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4755..4775
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   INTRAMEM        4806..4815
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        4836..4856
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        4857..4953
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          103..158
FT                   /note="MIR 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          165..210
FT                   /note="MIR 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          218..273
FT                   /note="MIR 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          279..336
FT                   /note="MIR 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          344..401
FT                   /note="MIR 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          592..802
FT                   /note="B30.2/SPRY 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          846..959
FT                   /note="1"
FT   REPEAT          960..1073
FT                   /note="2"
FT   DOMAIN          1018..1215
FT                   /note="B30.2/SPRY 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   DOMAIN          1350..1556
FT                   /note="B30.2/SPRY 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          2682..2800
FT                   /note="3"
FT   REPEAT          2802..2915
FT                   /note="4"
FT   REGION          846..2915
FT                   /note="4 X approximate repeats"
FT   REGION          1349..1370
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2344..2369
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3559..3588
FT                   /note="Interaction with CALM"
FT                   /evidence="ECO:0000250"
FT   REGION          3679..3705
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4196..4215
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4322..4349
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4406..4450
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        3690..3705
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4198..4215
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4330..4349
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1334
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1863
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         2021
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         2359
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:E9Q401"
FT   MOD_RES         2687
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         2787
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:E9Q401"
FT   MOD_RES         2798
FT                   /note="Phosphoserine; by CaMK2D and PKA"
FT                   /evidence="ECO:0000269|PubMed:18755143,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         2801
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         2804
FT                   /note="Phosphoserine; by CaMK2D"
FT                   /evidence="ECO:0000269|PubMed:18755143,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         2937
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:E9Q401"
FT   VAR_SEQ         1952
FT                   /note="R -> RKT (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:20471962"
FT                   /id="VSP_042299"
FT   VAR_SEQ         3694..3701
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:20471962"
FT                   /id="VSP_042300"
FT   CONFLICT        40
FT                   /note="E -> G (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        364
FT                   /note="W -> R (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1838
FT                   /note="Q -> R (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2691
FT                   /note="F -> S (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3216
FT                   /note="I -> T (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3226
FT                   /note="E -> G (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3355
FT                   /note="D -> N (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3541
FT                   /note="V -> I (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3751
FT                   /note="I -> T (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3885
FT                   /note="D -> G (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3990
FT                   /note="V -> A (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4196
FT                   /note="D -> G (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4262
FT                   /note="V -> A (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4536
FT                   /note="S -> G (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4667
FT                   /note="D -> G (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4930
FT                   /note="Y -> H (in Ref. 1; ABY79796)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3562..3571
FT                   /evidence="ECO:0007829|PDB:2K2F"
SQ   SEQUENCE   4953 AA;  562955 MW;  2C2798E8A2C4564A CRC64;
     MADAGEGEDE IQFLRTDDEV VLQCTATIHK EQQKLCLAAE GFGNRLCFLE STSNSKNVPP
     DLSICTFVLE QSLSVRALQE MLANTVEKSE GKFMMKTAQG GGHRTLLYGH AILLRHSYSG
     MYLCCLSTSR SSTDKLAFDV GLQEDTTGEA CWWTIHPASK QRSEGEKVRV GDDLILVSVS
     SERYLHLSYG NSSWRVDAAF QQTLWSVAPI SSGSEAAQGY LIGGDVLRLL HGHMDECLTV
     PSGEHGEEQR RTVHYEGGAV SVHARSLWRL ETLRVAWSGS HIRWGQPFRL RHVTTGKYLS
     LMEDKNLLLM DKEKADVKST AFAFRSSKEK LDAGVRKEVD GMGTSEIKYG DSICYIQHVD
     TGLWLTYQAV DVKSARMGSI QRKAIMHHEG HMDDGLNLSR SQHEESRTAR VIRSTVFLFN
     RFIRGLDALS KRAKLPTVDL PIESVSLSLQ DLIGYFHPPD EHLEHEDKQN RLRALKNRQN
     LFQEEGMINL VLECIDRLHV YSSAAHFADV AGREAGESWK SILNSLYELL AALIRGNRKN
     CAQFSGSLDW LISRLERLEA SSGILEVLHC VLVESPEALN IIKEGHIKSI ISLLDKHGRN
     HKVLDVLCSL CVCHGVAVRS NQHLICDNLL PGRDLLLQTR LVNHVSSMRP NIFLGVSEGS
     AQYKKWYYEL MVDHTEPFVT AEATHLRVGW ASTEGYSPYP GGGEEWGGNG VGDDLFSYGF
     DGLHLWSGCI ARTVSSPNQH LLRTDDVISC CLDLSAPSIS FRINGQPVQG MFENFNIDGL
     FFPVVSFSAG IKVRFLLGGR HGEFKFLPPP GYAACYEAVL PKEKLKVEHS REYKQERTYT
     RDLLGPTVSL TQAAFTPVPV DTSQIVLPPH LERIRERLAE NIHELWVMNK IELGWQYGPV
     RDDNKRQHPC LVEFCKLPEQ ERNYNLQMSL ETLKTLLALG CHVGIADEHA EEKVKKMKLP
     KNYQLTSGYK PAPMDLSFIK LTPSQEAMVD KLAENAHNVW ARDRIRQGWT YGIQQDVKNR
     RNPRLVPYTL LDDRTKKSNK DSLREAVRTL LGYGYHLEAP DQDHASRAEV CSGTGERFRI
     FRAEKTYAVK AGRWYFEFEA VTAGDMRVGW SRPGCQPDLE LGSDERAFAF DGFKAQRWHQ
     GNEHYGRSWQ AGDVVGCMVD MNEHTMMFTL NGEILLDDSG SELAFKDFDV GDGFIPVCSL
     GVAQVGRMNF GKDVSTLKYF TICGLQEGYE PFAVNTNRDI TMWLSKRLPQ FLQVPSNHEH
     IEVTRIDGTI DSSPCLKVTQ KSFGSQNSNT DIMFYRLSMP IECAEVFSKS VAGGIPGAGF
     YGPKNDLEDF DVDSDFEVLM KTAHGHLVPD RMDKDKETPK PEFNNHKDYA QEKPSRLKQR
     FLLRRTKPDY STSHSARLTE DVLADDRDDY EYLMQTSTYY YSVRIFPGQE PANVWVGWIT
     SDFHQYDTGF DLDRVRTVTV TLGDEKGKVH ESIKRSNCYM VCAGESMSPG QGRNNSNGLE
     IGCVVDAASG LLTFIANGKE LSTYYQVEPS TKLFPAVFAQ ATSPNVFQFE LGRIKNVMPL
     SAGLFKSEHK NPVPQCPPRL HVQFLSHVLW SRMPNQFLKV DVSRISERQG WLVQCLDPLQ
     FMSLHIPEEN RSVDILELTE QEELLQFHYH TLRLYSAVCA LGNHRVAHAL CSHVDEPQLL
     YAIENKYMPG LLRAGYYDLL IDIHLSSYAT ARLMMNNEFI VPMTEETKSI TLFPDENKKH
     GLPGIGLSTS LRPRMCFSSP SFVSISNECY QYSPEFPLDI LKAKTIQMLT EAVKEGSLHA
     RDPVGGTTEF LFVPLIKLFY TLLIMGIFHN EDLKHILQLI EPSVFKEAAT PEEEGGAPEK
     EISIDDSKLE VKEEAKAGKR PKEGLLQMKL PEPVKLQMCL LLQYLCDCQV RHRIEAIVAF
     SDDFVAKLQD NQRFRYNEVM QALNMSAALT ARKEFRSPPQ EQINMLLNFK DDKSECPCPE
     EIRDQLLDFH EDLMTHCGIE LDEDGSLDGS NDLTIRGRLL SLVEKVTYLK KKQAEKPVAS
     DSRKSSSLQQ LISETMVRWA QESVIEDPEL VRAMFVLLHR QYDGIGGLVR ALPKTYTING
     VSVEDTINLL ASLGQIRSLL SVRMGKEEEK LMIRGLGDIM NNKVFYQHPN LMRALGMHET
     VMEVMVNVLG GGESKEITFP KMVANCCRFL CYFCRISRQN QKAMFDHLSY LLENSSVGLA
     SPAMRGSTPL DVAAASVMDN NELALALREP DLEKVVRYLA GCGLQSCQML VSKGYPDIGW
     NPVEGERYLD FLRFAVFCNG ESVEENANVV VRLLIRRPEC FGPALRGEGG NGLLAAMEEA
     IKIAEDPSRD GPSPTSGSSK TLDAEEEEDD TIHMGNAIMT FYAALIDLLG RCAPEMHLIH
     AGKGEAIRIR SILRSLIPLG DLVGVISIAF QMPTIAKDGK VVEPDMSAGF CPDHKAAMVL
     FLDRVYGIEV QDFLLHLLEV GFLPDLRAAA SLDTAALSAT DMALALNRYL CTAVLPLLTR
     CAPLFAGTEH HASLIDSLLH TVYRLSKGCS LTKAQRDSIE VCLLSICGQL RPSMMQHLLR
     RLVFDVPLLN EHAKMPLKLL TNHYERCWKY YCLPGGWSNF GAASEEELHL SRKLFWGIFD
     ALSQKKYEQE LFKLALPCLS AVAGALPPDY MESNYVSMME KQSSMDSEGN FNPQPVDTSN
     ITIPEKLEYF INKYAEHSHD KWSMDKLANG WIYGEIYSDS SKIQPLMKPY KLLSEKEKEI
     YRWPIKESLK TMLAWGWRIE RTREGDSMAL YNRTRRISQT SQVSIDAAHG YSPRAIDMSN
     VTLSRDLHAM AEMMAENYHN IWAKKKKMEL ESKGGGNHPL LVPYDTLTAK EKAKDREKAQ
     DIFKFLQISG YAVSRGFKDL DLDTPSIEKR FAYSFLQQLI RYVDEAHQYI LEFDGGSRSK
     GEHFPYEQEI KFFAKVVLPL IDQYFKNHRL YFLSAASRPL CTGGHASNKE KEMVTSLFCK
     LGVLVRHRIS LFGNDATSIV NCLHILGQTL DARTVMKTGL DSVKSALRAF LDNAAEDLEK
     TMENLKQGQF THTRSQPKGV TQIINYTTVA LLPMLSSLFE HIGQHQFGED LILEDVQVSC
     YRILTSLYAL GTSKSIYVER QRSALGECLA AFAGAFPIAF LETHLDKHNV YSIYNTRSSR
     ERAALSLPAN VEDVCPNIPS LEKLMTEIIE LAESGIRYTQ MPHMMEVVLP MLCSYMSRWW
     EHGPENHPER AEMCCTALNS EHMNTLLGNI LKIIYNNLGI DEGAWMKRLA VFSQPIINKV
     KPQLLKTHFL PLMEKLKKKA AMVVSEEDHL KAEARGDMSE AELLILDEFT TLARDLYAFY
     PLLIRFVDYN RAKWLKEPNP EAEELFRMVA EVFIYWSKSH NFKREEQNFV VQNEINNMSF
     LITDTKSKMS KAAISDQERK KMKRKGDRYS MQTSLIVAAL KRLLPIGLNI CAPGDQELIA
     LAKNRFSLKD TEEEVRDVIR SNIHLQGKLE DPAIRWQMAL YKDLPNRAED TSDPERTVER
     VLDIANVLFH LEQVEHPQRS KKAVWHKLLS KQRKRAVVAC FRMAPLYNLP RHRAVNLFLQ
     GYEKSWIETE EHYFEDKLIE DLAKPGSELP EEDEAMKRVD PLHQLILLFS RTALTEKCKL
     EEDFLYMAYA DIMAKSCHDE EDDDGEEEVK SFEVTGSQRS KEKEMEKQKL LYQQARLHDR
     GAAEMVLQTF SASKGETGPM VAATLKLGIA ILNGGNSTVQ QKMLDYLKEK KDVGFFQSLA
     GLMQSCSVLD LNAFERQNKA EGLGMVTEEG SGEKVLQDDE FTCDLFRFLQ LLCEGHNSDF
     QNYLRTQTGN NTTVNIIIST VDYLLRVQES ISDFYWYYSG KDIIDEQGQR NFSKAIQVAK
     QVFNTLTEYI QGPCTGNQQS LAHSRLWDAV VGFLHVFAHM QMKLSQDSSQ IELLKELMDL
     QKDMVVMLLS MLEGNVVNGT IGKQMVDMLV ESSNNVEMIL KFFDMFLKLK DLTSSDTFKE
     YDPDGKGVIS KRDFHKAMES HKHYTQSETE FLLSCAETDE NETLDYEEFV KRFHEPAKDI
     GFNVAVLLTN LSEHMPNDTR LQTFLELAES VLNYFQPFLG RIEIMGSAKR IERVYFEISE
     SSRTQWEKPQ VKESKRQFIF DVVNEGGEKE KMELFVNFCE DTIFEMQLAA QISESDLNER
     SANKEESEKE RPEEQAPRMG FFSLLTVQSA LFALRYNVLT LVRMLSLKSL KKQMKRMKKM
     TVKDMVSAFF SSYWSVFVTL LHFVASVCRG FFRIVSSLLL GGSLVEGAKK IKVAELLANM
     PDPTQDEVRG DEEEGERKPL ESALPSEDLT DLKELTEESD LLSDIFGLDL KREGGQYKLI
     PHNPNAGLSD LMTNPIPVPE VQEKFQEQKV KEEKEGKEET KSEPEKAEGE DGEKEEKAKD
     DKGKQKLRQL HTHRYGEPEV PESAFWKKII AYQQKLLNYF ARNFYNMRML ALFVAFAINF
     ILLFYKVSTS SVVEGKELPT RTSSDAAKVT TSLDSSPHRI IAVHYVLEES SGYMEPTLRI
     LAILHTIISF FCIIGYYCLK VPLVIFKREK EVARKLEFDG LYITEQPSED DIKGQWDRLV
     INTQSFPNNY WDKFVKRKVM DKYGEFYGRD RISELLGMDK AALDFSDARE KKKPKKDSSL
     SAVLNSIDVK YQMWKLGVVF TDNSFLYLAW YMTMSVLGHY NNFFFAAHLL DIAMGFKTLR
     TILSSVTHNG KQLVLTVGLL AVVVYLYTVV AFNFFRKFYN KSEDGDTPDM KCDDMLTCYM
     FHMYVGVRAG GGIGDEIEDP AGDEYEIYRI IFDITFFFFV IVILLAIIQG LIIDAFGELR
     DQQEQVKEDM ETKCFICGIG NDYFDTVPHG FETHTLQEHN LANYLFFLMY LINKDETEHT
     GQESYVWKMY QERCWEFFPA GDCFRKQYED QLN
//
